Association between nafamostat mesylate and in-hospital mortality in patients with coronavirus disease 2019: A multicenter observational study
Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19).
However, it is not known whether its use is associated with reduced in-hospital mortality in …
However, it is not known whether its use is associated with reduced in-hospital mortality in …
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis
The COVID-19 epidemic has become a major international health emergency. Millions of
people have died as a result of this phenomenon since it began. Has there been any …
people have died as a result of this phenomenon since it began. Has there been any …
Development of a colorimetric assay for quantification of favipiravir in human serum using ferrihydrite
Y Moriiwa, N Oyama, R Otsuka, K Morioka, A Shoji… - Talanta, 2023 - Elsevier
We developed a colorimetric analytical method for favipiravir (FPV), a promising treatment
for COVID-19. FPV forms yellow complexes with ferrihydrite (Fh) by a ligand substitution …
for COVID-19. FPV forms yellow complexes with ferrihydrite (Fh) by a ligand substitution …
Nafamostat mesylate monotherapy in patients with moderate Covid-19: a single-center, retrospective study
T Soma, K Fujii, A Yoshifuji, T Maruki, K Itoh… - Japanese Journal of …, 2022 - jstage.jst.go.jp
抄録 Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat
mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome …
mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome …